Eliglustat Synthesis Using Metal Complexes for High Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for the production of Eliglustat, a glucosylceramide synthase inhibitor, are costly, inefficient, and generate significant waste due to the use of toxic reagents and elaborate steps like resolution, deprotection, and epimerization, leading to low yields of the desired (1R,2R) isomer.
Innovation Solution
A novel process involving a metal complex reaction with an aldehyde compound, followed by hydrolysis, protection, treatment with pyrrolidine, reduction, and deprotection, eliminates the need for toxic solvents and costly reagents, providing a simple, efficient, and scalable method for producing Eliglustat with high enantiomeric purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing processes for Eliglustat production are used, then the desired (1R,2R) isomer can be obtained, but the process is costly and generates significant waste due to toxic reagents and elaborate steps
Solution Approach 1:
The invention extracts and eliminates the harmful elements (toxic reagents, elaborate resolution steps, deprotection steps, epimerization steps) from the existing process while retaining the core function of producing the (1R,2R) isomer. The new process uses a streamlined asymmetric synthesis that directly produces the desired isomer without these harmful intermediate steps.
Solution Approach 2:
The invention changes the fundamental parameters of the synthesis approach by using a metal complex-catalyzed asymmetric reaction instead of traditional resolution methods. This parameter change transforms the process from one requiring multiple purification and manipulation steps to a direct asymmetric synthesis that inherently produces high enantiomeric purity.
2Manufacturing precision
If existing processes for Eliglustat production are used, then the desired (1R,2R) isomer can be obtained, but the process is inefficient with low yields
Solution Approach 1:
The invention performs the asymmetric induction at the very beginning of the synthesis through metal complex-catalyzed reaction, establishing the correct stereochemistry early in the process. This preliminary asymmetric action eliminates the need for subsequent resolution steps that would otherwise be required to achieve high enantiomeric purity, thereby improving overall yield.
Solution Approach 2:
The new process maintains continuous productive action by eliminating interruptive steps such as resolution, deprotection, and epimerization. The synthesis proceeds through a continuous sequence of productive transformations that directly build the desired molecule with correct stereochemistry, maximizing material throughput and yield.
3Manufacturing precision
If existing processes for Eliglustat production are used, then the desired (1R,2R) isomer can be obtained, but the process is complex with multiple steps
Solution Approach 1:
The invention merges multiple separate operations (asymmetric synthesis, protection, and final product formation) into a streamlined sequence where the metal complex-catalyzed reaction directly establishes the stereochemistry and the subsequent steps naturally follow without requiring separate resolution or deprotection operations. This merging reduces the total number of steps while maintaining high enantiomeric purity.
Solution Approach 2:
The metal complex catalyst serves multiple functions: it catalyzes the asymmetric reaction to establish stereochemistry, enables direct formation of the desired isomer without resolution, and facilitates a streamlined synthesis pathway. This multi-functional approach replaces multiple specialized steps (resolution, deprotection, epimerization) with a more universal catalytic system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high yields of Eliglustat with over 99% enantiomeric excess, reducing waste generation and operational costs, making it suitable for commercial-scale production.
Implementation Method 1
reaction of the aldehyde compound (II) with metal complex (I) in the presence of a base to obtain compound (III)
Implementation Method 2
hydrolysis of the compound (III) obtained from step (a) in presence of acid to obtain amine compound (IV)
Implementation Method 3
reducing the compound (VI) of stage (d) and converting to Eliglustat compound (A)
Data Source
AI summary
The present invention relates to an improved process for the preparation of N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide (A), which is known as ELIGLUSTAT and its pharmaceutically acceptable salts, comprising the formation of novel intermediate metal complex (III), which on hydrolysis in presence of acid provides amine compound (IV) (as described herein), which is treated with pyrrolidine and subsequently reduced to convert into Eliglustat (A).